PCA3 and posterior cortical atrophy: Several single- or few-biomarker assays based on urinary analysis, such as prostate cancer antigen-3 (PCA3) [14], SelectMDx [15], Mi-Prostate Score [16] and ExoDx [17] have been commercially available for detection of PCa, but have not yet been integrated into clinical guidelines or implemented in healthcare systems [3].